Anthony Armas
About Anthony Armas
Independent director of NextPlat Corp (NXPL). Age 34 as of April 28, 2025. Background in healthcare administration and management (7+ years) and operating experience as an executive in a dietary ingredient/delivery technology company. Education: undergraduate degree and MBA from Florida International University. Currently CEO of One Innovation Labs; previously EVP (2019–2021). Also serves on the board of The Leadership Learning Center at St. John Bosco Church. Prior to joining NextPlat’s Board, he served on the board of Progressive Care Inc. since July 2023 . The Board has determined he is an independent director under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| One Innovation Labs | Executive Vice President | 2019–2021 | Operating leadership in dietary ingredient manufacturing/delivery technology |
| Healthcare administration (various) | Administrator/Manager | 7 years (unspecified dates) | Industry operating experience; details not specified in proxy |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| One Innovation Labs | Chief Executive Officer | Current | Dietary ingredient manufacturer and delivery technology company |
| Progressive Care Inc. | Director | Since July 2023 | Board experience prior to joining NextPlat’s Board |
| The Leadership Learning Center at St. John Bosco Church | Board Member | Current | Non-profit engagement |
Board Governance
- Independence: Board determined Armas is independent; only Fernandez, Ellenoff, and Phipps are non-independent .
- Board composition: 8 directors, 6 independent .
- Committee assignments (2024): Member, Compensation Committee (Chair: Hector Delgado); not listed on Audit or Nominating .
- Attendance: Board held 2 meetings in 2024; each incumbent director attended at least 100% of Board and committee meetings for which they served .
- Committee activity (2024): Compensation Committee held no formal meetings but acted by written consent once; Audit Committee met 4 times; Nominating Committee acted by written consent once .
- Lead Independent Director: Hector Delgado (functions include leading executive sessions and liaison role) .
Fixed Compensation
| Year | Cash Retainer ($) | Committee/Chair Fees ($) | Meeting Fees ($) | Equity (Grant-Date Fair Value, $) | Total ($) |
|---|---|---|---|---|---|
| 2024 | 0 | 0 | 0 | 0 | 0 |
- Director pay program (2024): Non-employee directors (other than Rodney Barreto) received stock awards equivalent to $25,000 vesting over one year; Barreto received a $48,000 cash retainer .
- Note: Armas showed no director compensation for 2024 in the proxy’s director compensation table, suggesting appointment timing or grant deferral; program terms indicate equity retainer is typical for non-employee directors .
Performance Compensation
- No performance-conditioned director compensation or metrics disclosed for non-employee directors; Compensation Committee responsible for executive pay programs and equity plans .
- Clawback policy disclosed for executive officers in connection with restatements; no director-specific performance metrics disclosed .
Other Directorships & Interlocks
| Company | Type | Role | Potential Interlock/Conflict Notes |
|---|---|---|---|
| Progressive Care Inc. | Public company | Director since July 2023 | Disclosed as prior-to-NextPlat board role; no specific related-party transactions involving Armas disclosed in NXPL proxy |
| One Innovation Labs | Private | CEO | No transactions with NXPL disclosed; no related-party items involving Armas identified |
Expertise & Qualifications
- Healthcare industry operations and administration; leadership in product manufacturing/delivery technology; MBA from FIU .
- Adds sector expertise helpful to Compensation Committee deliberations on people/plan design for a healthcare-adjacent portfolio (Progressive Care LLC noted as a subsidiary context in broader proxy but no specific Armas tie beyond biography) .
Equity Ownership
| As-of Date | Shares Beneficially Owned | Percent of Class |
|---|---|---|
| April 28, 2025 | 60,566 | <1% |
- Ownership includes securities beneficially owned under SEC rules; no disclosure of pledging or hedging specific to Armas beyond company-wide insider trading policy .
- Company reports all Section 16 filings were timely in 2024; no delinquencies noted .
Governance Assessment
- Strengths:
- Independent director with seat on Compensation Committee; independent composition across committees aligns with Nasdaq requirements .
- Reported 100% attendance by incumbents in 2024 supports engagement .
- Personal share ownership (60,566) provides alignment despite no 2024 director compensation reported; overall non-employee director program designed to deliver equity retainer for alignment .
- Watch items:
- Compensation Committee did not hold formal meetings in 2024 (acted by consent once); Board met only twice—low cadence can draw investor scrutiny for oversight robustness, though all directors met attendance requirements .
- Company-level related-party transactions involved other insiders (Fernandez, Phipps, Barreto) but none disclosed for Armas; continue monitoring for any future cross-entity dealings given Armas’s external roles .
- Red flags specific to Armas: None disclosed—no related-party transactions, loans, pledging, or Section 16 delinquencies identified for Armas in the 2025 proxy .
Citations: